Riskpilot← Back to searchSign inGet full accessOPTISAN AS
ASActiveOrg 913661060Vækerøåsen 12B, 0282 OsloNon-specialised wholesale of food, beverages and tobacco · NACE 4639Est. 20142 employeeswww.houseofhungary.no
Revenue 2024
NOK 2,2M
+75% vs 2023
EBITDA margin
-193.4%
-28% vs 2023
Equity ratio
54.3%
Financial strength
Net profit 2024
NOK -4,4M
-29% vs 2023
| Revenue | NOK 2,2M | +75% |
| EBITDA | NOK -4,3M | -28% |
| Net profit | NOK -4,4M | -29% |
| Total assets | NOK 2,2M | +81% |
| Equity | NOK 1,2M | +248% |
| Employees | 2 | — |
Legal name
OPTISAN AS
Org number
913661060
Legal form
Aksjeselskap
NACE code
4639 · Non-specialised wholesale of food, beverages and tobacco
Founded
20. mai 2014
Share capital
NOK 52 719
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Import av næringsmidler for distribusjon og salg, samt alt som står i forbindelse. Selskapet kan også ha eierinteresser i andre selskaper av enhver art.
Address
Vækerøåsen 12B, 0282 Oslo
Website
www.houseofhungary.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77 | 252 | 309 | 465 | 729 | 773 | 410 | 2 180 | 2 063 | 1 262 | 2 213 |
| Staff expenses | −0 | −26 | −0 | −0 | −0 | −0 | −0 | −614 | −1 176 | −1 507 | −1 771 |
| EBITDA | −19 | −71 | −16 | −18 | −10 | −53 | 74 | −139 | −2 409 | −3 342 | −4 281 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −4 | −5 |
| EBIT | −19 | −71 | −16 | −18 | −10 | −53 | 74 | −139 | −2 409 | −3 347 | −4 286 |
| Net financials | −2 | −16 | −21 | −31 | −41 | −39 | −52 | −35 | −45 | −39 | −77 |
| Profit before tax | −20 | −87 | −37 | −49 | −51 | −92 | 22 | −174 | −2 454 | −3 386 | −4 362 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −20 | −87 | −37 | −49 | −51 | −92 | 22 | −174 | −2 454 | −3 386 | −4 362 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 60 | 38 | 33 | 583 | 335 | 186 | 76 | 1 219 | 1 110 | 1 209 | 2 185 |
| Equity | 4 | −83 | −119 | −168 | −219 | −311 | −289 | 538 | 884 | −801 | 1 187 |
| Long-term debt | 0 | 0 | 0 | 738 | 588 | 438 | 288 | 138 | 0 | 0 | 0 |
| Short-term debt | 56 | 120 | 153 | 14 | −33 | 59 | 77 | 544 | 226 | 2 010 | 998 |
| Total debt | 56 | 120 | 153 | 751 | 554 | 497 | 365 | 682 | 226 | 2 010 | 998 |
EBITDA margin
-193.4%
This company
15.8%
Market median
-1324% vs market
20142024
Equity ratio
54.3%
This company
38.2%
Market median
+42% vs market
20142024
Return on equity
-367.5%
This company
18.4%
Market median
-2097% vs market
20142024
Net profit margin
-197.1%
This company
8.1%
Market median
-2533% vs market
20142024
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20142024
Debt / equity
0.84×
This company
0.62×
Market median
+35% vs market
20142024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 17.0% | 17.0% | 2024 | |
Terminalpartner As | Company | 14.8% | 14.8% | 2024 |
| Individual | 7.4% | 7.4% | 2024 | |
Luzmon Medical As | Company | 5.4% | 5.4% | 2024 |
| Individual | 3.6% | 3.6% | 2024 | |
Next Frontier As | Company | 2.3% | 2.3% | 2024 |
Vero Invest As | Company | 3.1% | 3.1% | 2024 |
| Individual | 1.1% | 1.1% | 2024 | |
H Skree As | Company | 1.1% | 1.1% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OPTISAN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arild Gleditsch | Board of Directors | 0 companies |
| Houtan Houshangi | Board of Directors | 0 companies |
| Svein Sandor Bognar | Chairman | 0 companies |